{"id":251,"date":"2024-05-08T17:32:54","date_gmt":"2024-05-08T17:32:54","guid":{"rendered":"https:\/\/www.libertymanagement.us\/fda-news\/?p=251"},"modified":"2024-05-08T17:32:54","modified_gmt":"2024-05-08T17:32:54","slug":"self-identification","status":"publish","type":"post","link":"https:\/\/www.libertymanagement.us\/fda-news\/2024\/05\/08\/self-identification\/","title":{"rendered":"SELF-IDENTIFICATION"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The FDA <a href=\"https:\/\/www.fdahelp.us\/fda-self-identification.html\">Self-Identification<\/a>\napplies to facilities and organizations involved in the development and\nmanufacturing of generic drugs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Facilities that manufacture or intend to manufacture must submit\nSelf-Identification.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><a href=\"https:\/\/www.fdahelp.us\/api-listing.html\">Active\nPharmaceutical Ingredients<\/a> (API) of human generic drugs.<\/li><li>Finished Dosage Forms (FDF) of human generic\ndrugs.<\/li><li>Sites and organizations involved in:<\/li><li>Bioequivalence (BE)\/bioavailability (BA) sites\nthat are registered as a generic drug submission and conduct clinical BE\/BA\ntesting, bioanalytical testing of samples collected from clinical BE\/BA\ntesting, and\/or in vitro BE testing)<\/li><li>Testing, repackaging, or relabeling of generic\ndrugs (exempt from user fees)<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Self-Identification must be submitted via CDER Direct or ESG\nportal by generating SPL files.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under GDUFA, if a facility fails to self-identify, all FDF\nor API products manufactured at the facility and all FDFs containing APIs\nmanufactured at the facility will be deemed misbranded.&nbsp; It is a violation of federal law to ship\nmisbranded products in interstate commerce or to import them into the United\nStates. Such violations can result in prosecution of those responsible,\ninjunctions, or seizures of misbranded products. Products are considered as\nmisbranded because of failure of the facility to self-identify are subject to\nbeing denied entry into the United States.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Self-identification must be submitted between May 1 and June\n1 of each year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/www.fdahelp.us\/\">Liberty Management Group LTD<\/a>, as a leading FDA consulting firm provides assistance with SPL preparation and submission of Self-Identification to FDA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sudha S<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Regulatory Consultant<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Email: office@libertymanagement.us<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">www.fdahelp.us<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA Self-Identification applies to facilities and organizations involved in the development and manufacturing of generic drugs. Facilities that manufacture or intend to manufacture must submit Self-Identification. Active Pharmaceutical Ingredients (API) of human generic drugs. Finished Dosage Forms (FDF) of human generic drugs. Sites and organizations involved in: Bioequivalence (BE)\/bioavailability (BA) sites that are registered &hellip; <a href=\"https:\/\/www.libertymanagement.us\/fda-news\/2024\/05\/08\/self-identification\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SELF-IDENTIFICATION&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[42],"class_list":["post-251","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-fda-drug-registration"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/comments?post=251"}],"version-history":[{"count":1,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/251\/revisions"}],"predecessor-version":[{"id":252,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/251\/revisions\/252"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/media?parent=251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/categories?post=251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/tags?post=251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}